Disclosure Of NDA Filings Recommended In Transparency Report
This article was originally published in The Tan Sheet
Executive Summary
Firms may have to marshal legal arguments to prevent public disclosure of drug development milestones, including OTC switch filings, following the FDA Transparency Task Force's recommendation that the agency disclose when applications are submitted and withdrawn
You may also be interested in...
FDA Unveils Plan To Boost Transparency To Industry
FDA has identified 19 steps to improve its communications with drug and medical device manufacturers, promising quicker responses to industry questions.
FDA Unveils Plan To Boost Transparency To Industry
FDA has identified 19 steps to improve its communications with drug and medical device manufacturers, promising quicker responses to industry questions.
FDA Unveils Plan To Boost Transparency To Industry
FDA identified 19 steps to improve its communications with drug and medical device manufacturers, promising quicker responses to industry questions.